Law News, Briefings, Reports, & Legal Intelligence Resources
Class Action

Indivior Pleads Guilty to Marketing Fraud, Agrees to $600M Settlement

The Virginia-based pharmaceutical company admitted that it provided false information about Suboxone, a medication to treat opioid addiction.
By Simpluris Research
  • Share

Reuters reported the U.S. Justice Department's (DoJ) announcement that Indivior Solutions pled guilty to a felony charge of its marketing scheme to boost opioid prescriptions by falsely claiming that its medication, Suboxone Film, was "safer, less divertible, and less abusable than other opioid-addiction treatment drugs." The pharmaceutical company also falsely advertised a "Here to Help" program--a so-called online and phone resource--for opioid addicts who could contact doctors. However, the company knew those doctors were prescribing the medication "at high rates and in a clinically unwarranted manner." To resolve criminal and civil liability associated with Suboxone, Indivior Solutions and its parent companies Indivior Inc. and Indivior PLC agreed to pay a total of $600 million. 

Suboxone is a drug that contains opioids used to treat opioid addiction and withdrawal. Its brand names are Bunavail, Suboxone, and Zubsolv. Suboxone consists of buprenorphine and naloxone. Buprenorphine is a partial opiate agonist, which means it contains a very low dose of opioids that "activate the opioid receptors in the brain, but to a much lesser degree than a full agonist," like heroin, morphine, and opium. Naloxone is a pure opioid antagonist, blocking the rewarding effects of buprenorphine, including feelings of well-being, pain relief, and euphoria that can lead to addiction. The combination of the two drugs helps to wean a patient off of opioids.

Today’s announced resolution and related actions hold accountable entities and individuals that unlawfully marketed opioid-addiction products.
- Claire M. Murray, Principal Deputy Associate Attorney General

Even though the "highs" in Suboxone are relatively low to the full agonists, it still is highly addictive and cannot be administered alone. According to American Addiction Centers, the medication "has caused its own epidemic that requires its own course of treatment (pharmacological and psychological) to remedy."

According to the DoJ's indictment filed in 2019, "Indivior developed Suboxone Film around 2007 as a patent-protected alternative to the tablet form of Suboxone, which was then about to face generic drug competition...Indivior promoted Suboxone Film as safer and less-divertible than its tablet form, even though the company lacked any scientific evidence to support those claims. In particular, Indivior aggressively marketed Suboxone Film, without an established basis, as having a 'lower risk of child exposure' and a 'less divertible/abusable formulation.' Indivior made these and other false and misleading claims in marketing materials and through representations to physicians, pharmacists, and health care benefit programs throughout the country."

The indictment also claims that in furthering its scheme, "Indivior announced a 'discontinuance' of its tablet form of Suboxone based on supposed 'concerns regarding pediatric exposure to' tablets, when in fact Indivior executives knew the primary reason for the discontinuance was to delay the Food and Drug Administration’s approval of generic tablet forms of the drug."

Indivior’s fraudulent marketing was "highly successful, converting thousands of opioid-addicted patients over to Suboxone Film and causing state Medicaid programs to expand and maintain coverage of Suboxone Film at substantial cost to the government. Until earlier this year, when Suboxone Film became subject to generic competition, Indivior retained a high portion of the opioid-addiction treatment market."

The DoJ indicted Indivior with "conspiracy to commit wire fraud, mail fraud, and health care fraud. In addition, the indictment charges the company with one count of health care fraud, four counts of mail fraud, and twenty-two counts of wire fraud."

U.S. Department of Health and Human Services

U.S. Department of Health and Human Services

Opioid statistics in the U.S. as of October 2019

On Friday, Indivior pleaded guilty to "a one-count felony criminal information charging false statements relating to health care matters" and "admitted to making false statements to promote the film version of Suboxone (Suboxone Film) to the Massachusetts Medicaid program (MassHealth) relating to the safety of Suboxone Film around children. The resolution included a criminal fine, forfeiture, and restitution totaling $289 million. On June 30, 2020, Indivior PLC’s former CEO Shaun Thaxter pleaded guilty to a one-count misdemeanor information related to Indivior’s false and misleading representations to MassHealth."

"Specifically, Indivior Solutions admitted that, in October 2012, it sought to convince MassHealth to expand Medicaid coverage of Suboxone Film in Massachusetts and sent MassHealth false data indicating that Suboxone Film had the lowest rate of accidental pediatric exposure (i.e., children taking medication by accident) of all buprenorphine drugs in Massachusetts, when in fact, it did not. Indivior Solutions further admitted that sending the false and misleading information occurred in the context of marketing and promotional efforts directed at MassHealth, which were overseen by top executives. MassHealth announced it would provide access to Suboxone Film for patients with children under the age of six shortly after Indivior provided the false and misleading information to agency officials."

Other provisions in the agreement included:

  • Require Indivior Inc. to disband its Suboxone sales force and not reinstate it;
  • Require Indivior Inc.’s CEO to personally certify, under penalty of perjury, on an annual basis that during the prior year (a) Indivior was in compliance with the Food Drug and Cosmetic Act and did not commit health care fraud or (b) list all non-compliant activity and the steps taken by Indivior to remedy these acts;
  • Prohibit Indivior Inc. from using data obtained from surveys of health care providers for marketing, sales, and promotional purposes;
  • Require Indivior Inc. to remove health care providers from their promotional programs who are at a high risk of inappropriate prescribing; and
  • Make Indivior subject to contempt sanctions by the court and reinstatement of the dismissed charges if it violates the agreement.

In the DOJ's press release, Principal Deputy Associate Attorney General Claire M. Murray said, “Combatting the opioid crisis is a Department of Justice priority. Today’s announced resolution and related actions hold accountable entities and individuals that unlawfully marketed opioid-addiction products.”

Deputy Assistant Attorney General Michael D. Granston for the Justice Department's Civil Division emphasized "The opioid crisis is a public health emergency. Prevention and access to effective treatments for opioid addiction are critical to fighting this epidemic. When a drug manufacturer claims to be part of a solution for opioid addicts, we expect honesty and candor to government officials, as well as to the physicians and patients making important treatment decisions based on those representations.”

The Centers for Disease Control and Prevention reported that "More than 750,000 people have died since 1999 from a drug overdose. Two out of three drug overdose deaths in 2018 involved an opioid...Overdose deaths involving opioids, including prescription opioids, heroin, and synthetic opioids (like fentanyl), have increased almost six times since 1999...and 32% of those deaths involved prescription opioids." In 2017, the U.S. Department of Health and Human Services (HHS) declared a public health emergency to address the opioid crisis. That April, President Trump announced a five-point strategy to combat the epidemic. A multilateral effort among various government agencies including the HHC, Food and Drug Administration, Agency, and Federal Trade Commission continues to ensure opioid manufacturers adhere to lawful practices and truthfully marketed.

Get Unlimited Access To Simpluris Insights—FREE
We won't ever sell your information. We'll only send a brief summary of legal industry news once in a while.
Schedule a free, expert consultation with a Simpluris Project Manager
So that we may best serve you, please let us know the following:
Ascertainability Numerosity
Federal-Rule-of-Civil-Procedure-23 Class-action-certification
We're excited to learn about your business.
First, a bit about you.
Something went wrong. Please try again
Class members may visit our case lookup screen to locate information related to your case.
Hi , do any of the following times work for you?
Hi , Please call us at 714-640-5606
All times are . Please allow for 30 minutes.
All available appointment slots are booked for the next few days.
  • Today

  • Tomorrow

  • Day After Tomorrow

  • Day 4

  • Day 5

  • Day 6

Please select at least one time slot.
Something went wrong. Please try again
Thanks , we look forward to meeting you !
Check your email for more info and a calendar invitation.